A thought occurred to me today. In one of Otonomy's press releases, they mentioned that they had "successfully escalated through three dose levels totaling 24 patients and have nearly completed enrollment of patients in the high dose cohort" for OTO-413. I may be interpreting this incorrectly, but it sounds like they're doing their Phase I/II dosage testing incrementally in groups.
I wonder if this is standard and what Frequency Therapeutics is doing too. 96 patients (their original goal) would break-up nicely into 3 groups of 32. Each of these groups could have 8 placebo patients. If they were to do it this way, then it would mean they have completed the first dosage group (1 dose of FX-322), and that the other two groups were still in progress (2 doses and 4 doses).
The end result of the study would be the same, but doing it this way would have the following consequences:
* Interim results would not be possible, as the most important group would not finish until the end of the study.
* The study would have to enroll a number of patients near its set goal of 96.
Could this be how Frequency Therapeutics' study is setup? If so, it would mean that only recently has anymore been given 4 doses of FX-322.
[1]
https://investors.otonomy.com/news-...rts-second-quarter-2020-financial-results-and